Dashboard
Manage Tickers

AIM AIM ImmunoTech Inc.


$ 1.33 $ 0.07 (5.38 %)    

Friday, 21-Nov-2025 15:05:45 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
QQQ $ 589.68 $ 4.40 (0.75 %)
DIA $ 462.34 $ 5.05 (1.1 %)
SPY $ 658.48 $ 6.50 (1 %)
TLT $ 89.48 $ 0.27 (0.3 %)
GLD $ 373.65 $ -0.58 (-0.15 %)
$ na
$ 1.30
$ 1.33 x 100
$ 1.36 x 35
$ 1.27 - $ 1.31
$ 0.06 - $ 20.35
22,040
na
3.71M
$ -1.79
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

aim-immunotech-enters-note-purchase-agreement-for-33m-unsecured-promissory-note-with-streeterville-capital-in-private-placement
AIM ImmunoTech Enters Note Purchase Agreem...
11/19/2025 12:11:51

aim-immunotech-q3-eps-157-misses-098-estimate-sales-26000k-down-from-35000k-yoy
AIM ImmunoTech Q3 EPS $(1.57) Misses $(0.9...
11/18/2025 13:57:24

AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(1.57) per share which missed the analyst consensus estimate of $(0.98)...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
11/17/2025 21:07:48

earnings-scheduled-for-november-12-2025
Earnings Scheduled For November 12, 2025
11/12/2025 11:11:28

12-health-care-stocks-moving-in-tuesdays-after-market-session
12 Health Care Stocks Moving In Tuesday's ...
11/11/2025 21:07:32

aim-immunotech-presents-data-from-phase-2-advanced-recurrent-ovarian-cancer-clinical-trial-across-27-participants
AIM ImmunoTech Presents Data From Phase 2 ...
11/10/2025 14:01:25

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today detailed a recent abstract containing data from t...

aim-immunotech-says-data-from-completed-phase-2-cisplatin-resistant-advanced-recurrent-ovarian-cancer-clinical-study-utilizing-ampligen-accepted-in-late-breaking-abstract-at-annual-sitc-meeting
AIM ImmunoTech Says Data From Completed Ph...
11/04/2025 14:08:37

aim-immunotech-granted-european-patent-for-ampligen-in-long-covid-treatment
AIM ImmunoTech Granted European Patent For...
11/03/2025 13:57:02

ascendiant-capital-maintains-buy-on-aim-immunotech-lowers-price-target-to-24
Ascendiant Capital Maintains Buy on AIM Im...
10/03/2025 10:19:56

Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $150 t...

aim-immunotech-secures-japanese-patent-for-ampligen-in-combination-with-checkpoint-inhibitors-for-the-treatment-of-cancer
AIM ImmunoTech Secures Japanese Patent For...
09/25/2025 12:46:47

aim-immunotech-has-been-granted-european-patent-number-ep4096675-titled-compositions-for-treating-long-covid
AIM ImmunoTech Has Been Granted European P...
09/22/2025 19:58:47

https://register.epo.org/application?number=EP21818146

aim-immunotech-says-jitc-publishes-new-peer-reviewed-article-providing-evidence-of-combination-effect-of-aims-drug-ampligen-and-interferon-alpha-on-tumor-growth-and-subsequent-subject-survival
AIM ImmunoTech Says JITC Publishes New Pee...
09/22/2025 13:05:11

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the Journal for ImmunoTherapy of C...

aim-immunotech-q2-eps-368-beats-800-estimate-sales-2500k-miss-10000k-estimate
AIM ImmunoTech Q2 EPS $(3.68) Beats $(8.00...
08/15/2025 13:11:57

AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(3.68) per share which beat the analyst consensus estimate of $(8.00) b...

Core News & Articles
Earnings Scheduled For August 14, 2025
08/14/2025 08:32:32

uncovering-potential-aim-immunotechs-earnings-preview
Uncovering Potential: AIM ImmunoTech's Ear...
08/13/2025 16:01:47

aim-immunotech-announces-that-its-drug-ampligen-will-be-featured-in-four-presentations-at-upcoming-5th-annual-marie-sklodowska-curie-symposium-on-cancer-research-and-care-in-warsaw-poland
Aim Immunotech Announces That Its Drug Amp...
08/06/2025 13:04:59

AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the strong clinical successes in o...

aim-immunotech-announces-company-update-including-mid-year-report-of-ampligen-in-combination-with-astrazenecas-imfinzi-for-treatment-of-pancreatic-cancer-demonstrating-signs-of-both-no-significant-toxicity-and-superior-pfs-and-oscompany-also-bolstered-cash-position-to-fund-operations-for-12-months
AIM ImmunoTech Announces Company Update In...
08/04/2025 13:06:24

Primary focus on pancreatic cancerMid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (d...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
07/29/2025 17:06:19

crude-oil-gains-over-1-unitedhealth-earnings-miss-views
Crude Oil Gains Over 1%; UnitedHealth Earn...
07/29/2025 16:53:28

us-stocks-mixed-procter--gamble-posts-upbeat-earnings
US Stocks Mixed; Procter & Gamble Posts Up...
07/29/2025 14:13:18

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION